Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CCNC | P24863 | 4/20 | 0.47 |
| ▸ | CDK8 | P49336 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GPR6 | P46095 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6121111 | 0.84 | GAA (0.71) | SIGMAR1GAAPOLBCCNCCDK8 | |
| SCHEMBL31297972 | 0.83 | HRH4 (0.45) | SIGMAR1GAAMEN1RAB9AKMT2A | |
| Hydrochloric Acid SCHEMBL29268525 | 0.83 | GAA (0.69) | SIGMAR1GAAPOLBCCNCCDK8 | |
| SCHEMBL31298051 | 0.81 | KMT2A (0.62) | GAAPOLBMEN1RAB9AKMT2A | |
| SCHEMBL31298071 | 0.78 | GAA (0.43) | GAARAB9AALDH1A1TSHRHSD17B10 | |
| SCHEMBL7108628 | 0.76 | CA2 (0.43) | SIGMAR1POLBCCNCCDK8 | |
| SCHEMBL31298011 | 0.76 | L3MBTL3 (0.52) | GAAMEN1KMT2A | |
| SCHEMBL6403300 | 0.75 | GAA (0.47) | GAARAB9AALOX5 | |
| SCHEMBL28393 | 0.74 | SIGMAR1 (1.00) | SIGMAR1POLBCCNCCDK8USP2 | |
| SCHEMBL894920 | 0.74 | SIGMAR1 (1.00) | SIGMAR1POLBCCNCCDK8USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250043353-A1 | BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2025-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250043353-A1 | BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE | WNT1, XPOT, CTNNBL1 | SIGMAR1 4495/4885GAA 4758/4885POLB 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.